Guardian Pharmacy Services, Inc. (NYSE:GRDN) Given Average Recommendation of “Moderate Buy” by Brokerages

Guardian Pharmacy Services, Inc. (NYSE:GRDN) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $42.8333.

Several equities research analysts have issued reports on the company. UBS Group reaffirmed a “buy” rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Zacks Research downgraded Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Truist Financial raised their price target on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America raised their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Wall Street Zen downgraded Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th.

Institutional Investors Weigh In On Guardian Pharmacy Services

Hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its holdings in shares of Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after buying an additional 345 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Guardian Pharmacy Services during the second quarter worth $43,000. State of Wyoming acquired a new stake in shares of Guardian Pharmacy Services during the second quarter worth $58,000. Strs Ohio acquired a new stake in shares of Guardian Pharmacy Services during the fourth quarter worth $75,000. Finally, Clearstead Advisors LLC lifted its holdings in shares of Guardian Pharmacy Services by 196.3% during the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after buying an additional 1,741 shares in the last quarter.

Guardian Pharmacy Services Trading Up 0.5%

NYSE GRDN opened at $42.64 on Friday. The company has a market cap of $2.12 billion, a PE ratio of 51.38, a PEG ratio of 2.78 and a beta of 0.08. Guardian Pharmacy Services has a 12 month low of $19.30 and a 12 month high of $44.00. The stock has a 50 day moving average of $38.65 and a 200-day moving average of $34.56.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The business had revenue of $336.60 million during the quarter, compared to the consensus estimate of $329.89 million. During the same quarter last year, the firm posted $0.22 EPS. The company’s quarterly revenue was up 2.2% on a year-over-year basis. As a group, sell-side analysts predict that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.